Given that patient-derived tumor samples are usually only obtained before treatment and/or after the end of treatment and thus can only capture the long-term effects of this therapy (28, 30, 32), our observations also highlight the importance of investigating the short- and medium-term effects of anti-HER2 therapies over the immunosuppressive state of the human TME. This evidence concerns the gene ERBB2 and neoplasm.